Actualités marché

Berg Biosystems and Berg Diagnostics, members of the Berg Pharma group of companies (Boston), presented "Novel Autism Spectrum Disorder (ASD) Biomarker Discovery Using the Berg Interrogative Biology Discovery Platform" at US-HUPO meeting in San...

Led by tissue tests to aid drug therapy decisions, the personalized medicine testing market exceeded $28 billion in 2011, according to Kalorama Information. The healthcare market research publisher includes in its analysis all tests that are used to determine the appropriate therapeutic on an individual patient.This broad scope includes new molecular tests based on proven biomarkers, as well as routine glucose and microbial identification tests. The dynamic part of the market is the new tests, and according to Kalorama's report, "World Market for Personalized Medicine Diagnostics," the tests that have turned personalized medicine from concept to reality are tissue tests that determine therapy for cancer. These will experience better than average IVD industry revenue growth rates in the next five years.

Verinata Health Inc.(Redwood City, CA) has launched a non-invasive prenatal test that can detect fetal chromosomal abnormalities early in a pregnancy using maternal plasma. The test uses DNA sequencing to detect fetal chromosomal aneuploidies such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13). According the the company, its test has better accuracy than maternal serum screening tests currently available.

Bringing a radical technology to market is very difficult but the rewards can be phenomenal. Many large companies have put significant or risky R&D programmes on hold until economic conditions improve, and so start-ups are increasingly seen as the lifeblood of innovation in the medical device sector. Ignoring these young firms until their ideas are developed further could be a costly mistake...

Bulletin Electronique des Ambassades de France aux Etats-Unis -

Si la notion d'ADN a fait son apparition vers la fin du 19ème siècle, il aura fallu attendre l'année 1953 pour que sa structure en double hélice soit découverte et 2001 pour qu'une première version (incomplète) du génome humain soit publiée. Depuis, les méthodes de séquençage ne cessent d'évoluer ... nous revenons sur les différents dispositifs disponibles aujourd'hui pour séquencer l'ADN et sur les technologies de demain. Bientôt le génome humain pourrait être séquencé en quelques heures et plus incroyable encore à l'aide d'un dispositif de la taille d'une clé USB !

Dako has entered into a new collaboration agreement with Amgen Inc. on the development of a diagnostic test for an Amgen cancer drug candidate in clinical development. “It is Dako’s mission to fight cancer.

FDA Approves Gen-Probe Incorporated's And DiagnoCure Inc.'s PROGENSA PCA3 Assay, First Urine-Based Molecular Test To Help Determine Need For Repeat Prostate Biopsies

The Medicines and Healthcare products Regulatory Agency (MHRA), a British regulatory body, has issued an alert for reagents requiring manual handling on Hitachi’s Cobas c501/502 laboratory analyzer.

SAN DIEGO, CA--(Marketwire -03/12/12)- Quidel Corporation (NASDAQ: QDEL - News), a leading provider of rapid diagnostic testing solutions and cell-based virology assays, announced today that it has received the CE Mark for the Quidel Molecular RSV ...

Alere Inc. has entered into a binding agreement to purchase eScreen Inc., a technology firm that specializes in toxicology screening and employee health products and services.

Exonhit was awarded a €418,000 grant from the European Union’s 7th Framework Program (FP7) to fund its participation in the Responsify Consortium, which is focused on the development of biomarker-based assays to predict tumor responses to the anticancer drugs Herceptin and Avastin. The ultimate aim of the project is to develop marked IVD tests for use in current clinical practice.

Abbott (NYSE: ABT) announced today it will collaborate with Genetics Laboratory, Inc. (GenLab) on the development of a molecular diagnostic test that will be designed to rapidly detect microorganisms that cause orthopedic infections. Under terms of the agreement, Abbott, in conjunction with GenLab, will develop and commercialize the new assay for use on the PLEX-ID automated microbial identification system.

Fiomi Diagnostics, a maker of point-of-care heart assays in Sweden, has been acquired by Irish diagnostics company Trinity Biotech in a deal worth up to $13.1 million. Fiomi's flagship product is an assay for troponin I, an established heart attack biomarker. Fiomi estimates the size of the global troponin I testing market at $450 million.

GE Global Research, GE's central technology development arm, has been awarded a program through the Defense Advanced Research Projects Agency (DARPA) to develop a medical device that can diagnose at point of care the flu and other infectious diseases ...

LONDON (Reuters) - The lives of almost a million newborn babies could be saved every year if simple, cheap and rapid tests for syphilis were offered to pregnant women in poorer countries, global health...

Nanostart holding Lumiphore announced the European launch of three diagnostic tests by its partner ThermoFisher Scientific Clinical Diagnostics using Lumiphore's time-resolved fluorescent reporter technology. ThermoFisher Clinical Diagnostics has launched three CE-marked in vitro diagnostic tests in countries of the European Economic Area (EEA)